13F Holdings
中文EN

GLUC Glucose Health, Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1420108 · Fiscal year ends 12/31

Financial factors as of 2017-09-30 (2017Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-70.6%
TTM net income YoY73.8%
TTM EPS YoY—
Revenue 3-yr CAGR237.6%
Net income 3-yr CAGR—

Margins

Gross margin65.4%
Operating margin-36.8%
Net margin-96.5%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-241.9%
ROIC (approx.)—
Asset turnover2.51x

Leverage & solvency

Liabilities / assets1,717.4%
Debt / equity—
Current ratio0.06x
Interest coverage-0.29x

Cash quality & payout

Operating cash flow / net income0.20x
Accruals ratio-192.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20162016-12-31FY20152015-12-31FY20142014-12-31FY20132013-12-31FY20122012-12-31
Income statement
Revenue$313,229$4,272$2,739$224—
Cost of revenue$294,062$3,875$2,636$2,315—
Gross profit$19,167$397-$20,726-$2,091—
R&D expense—$48$4,000——
SG&A expense$51,838$114,820$16,298$39,497$5,767
Operating income-$86,647-$156,173-$545,216-$1.27M-$361,423
Interest expense$323,796$120,028$109,631$168,862$37,655
Pretax income-$410,443-$266,064-$669,409-$1.46M-$399,078
Net income-$410,443-$266,064-$669,409-$1.46M-$399,078
EPS (basic)-0.15-0.14-0.99-4.91-0.05
EPS (diluted)—————
Balance sheet
Cash & equivalents$20,542$2,055$4,871$711$1,076
Receivables$11,724$3,150———
Inventory—$8,370$0$24,879—
Current assets$32,905$15,107$43,730$25,590$1,076
Total assets$33,145$15,407$44,030$25,590$207,676
Current liabilities$528,592$403,226$324,582$223,348$185,476
Short-term debt——$169,923$78,715—
Total liabilities$528,592$403,226$324,582$223,348$185,476
Shareholders' equity-$495,447-$387,819-$280,552-$197,758$22,200
Shares outstanding3.31M2.45M1.31M377,45610.11M
Cash flow statement
Operating cash flow-$39,263-$115,776-$135,352-$131,985-$83,691
Investing cash flow$250-$250———
Financing cash flow$57,500$113,210$139,512$131,620$78,600
Stock-based compensation$1,875$32,775———

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.